- About CW
- Topics
- Events
- Research
- Awards
- CW Connect
- Membership
“For tracking litigation, enforcement, and regulatory developments, Compliance Week
should be your prime source.”- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
SEC’s Ceresney: Common FCPA Violations in Pharma Industry
Image: From remarks last week at a conference in Washington D.C., SEC Director of Enforcement Andrew Ceresney highlighted three types of Foreign Corrupt Practices Act misconduct that most often arise in the pharmaceutical industry: pay-to-prescribe, formulary drugs, and charitable contributions. More of Ceresney’s observations are inside.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
Article
Mitigating FCPA Risks in Pharma, Med Device Sectors
Image: SEC Enforcement Director Andrew Ceresney recently dropped new hints on FCPA risks for pharma and medical devices, plus suggestions on how to avoid those risks. “Our FCPA focus obviously covers many industries,” he said. “But the pharma industry is one on which we have been particularly focused in recent ...
-
Basic PageSEC drops Binance lawsuit as Trump admin continues reshaping crypto enforcement
The Securities and Exchange Commission dropped its case against cryptocurrency exchange Binance, just the latest in a string of dismissals that highlight the SEC’s change of course under the crypto-friendly Trump administration.
-
PremiumUK regulator’s efforts to coax self-reporting fraud could fall flat, experts warn
To both clean up corporate behaviour and rack up its own enforcement record, the UK’s anti-bribery agency has seemingly largely guaranteed companies a pass from prosecution if they spill the beans on their misconduct. There’s only one problem: experts believe businesses may still stand a better outcome if they front ...